VRDN
NASDAQ · Biotechnology
Viridian Therapeutics Inc
$16.61
-0.39 (-2.29%)
Performance
1D
—
1W
—
1M
—
3M
-43.89%
6M
-41.58%
1Y
+26.60%
YTD
-45.86%
Open$17.00
Previous Close$17.00
Day High$17.14
Day Low$16.42
52W High$34.29
52W Low$11.76
Volume—
Avg Volume4.63M
Market Cap1.80B
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$31.51
Below
SMA 200
$22.43
Below
RSI (14)
17.6
Oversold
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
25 analysts
Price Target
+284.3% upside
Current
$16.61
$16.61
Target
$63.84
$63.84
$43.31
$63.84 avg
$68.31
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 90.35M | 891.8K | 430.67M |
| Net Income | -436,846,791 | -725,406,968 | -19,976,292 |
| Profit Margin | -483.6% | -84,917.7% | -4.6% |
| EBITDA | -464,842,443 | -846,793,579 | -30,128,222 |
| Free Cash Flow | — | — | -23,390,816 |
| Rev Growth | +242.1% | -53.3% | -2.2% |
| Debt/Equity | 0.12 | 0.03 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |